{"organizations": [], "uuid": "889b9f009ebeb6ba242e641f6ea4451676b15022", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-adaptimmune-announces-positive-saf/brief-adaptimmune-announces-positive-safety-data-from-pilot-studies-with-mage-a10-spear-t-cells-idUSFWN1P30PO", "country": "US", "domain_rank": 408, "title": "BRIEF-Adaptimmune Announces Positive Safety Data From Pilot Studies With MAGE-A10 SPEAR T-Cells", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.294, "site_type": "news", "published": "2018-01-08T21:13:00.000+02:00", "replies_count": 0, "uuid": "889b9f009ebeb6ba242e641f6ea4451676b15022"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-adaptimmune-announces-positive-saf/brief-adaptimmune-announces-positive-safety-data-from-pilot-studies-with-mage-a10-spear-t-cells-idUSFWN1P30PO", "ord_in_thread": 0, "title": "BRIEF-Adaptimmune Announces Positive Safety Data From Pilot Studies With MAGE-A10 SPEAR T-Cells", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "adaptimmune therapeutics plc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Adaptimmune Therapeutics Plc::\n* ADAPTIMMUNE ANNOUNCES POSITIVE SAFETY DATA FROM PILOT STUDIES WITH MAGE-A10 SPEAR T-CELLS AND FIRST PATIENT TO RECEIVE 1 BILLION TARGET CELL DOSE\n* ADAPTIMMUNE THERAPEUTICS PLC - NO EVIDENCE OF TOXICITY RELATED TO OFF-TARGET BINDING OR ALLOREACTIVITY HAS BEEN OBSERVED\n* ADAPTIMMUNE - IN NSCLC STUDY, THERE HAS BEEN ONE SERIOUS ADVERSE EVENT OF CYTOKINE RELEASE SYNDROME, A GRADE 4 EVENT THAT RESOLVED WITH TREATMENT\n* ADAPTIMMUNE THERAPEUTICS PLC - ADVERSE EVENT OF CYTOKINE RELEASE SYNDROME IN NSCLC STUDY LED TO COHORT 1 EXPANSION FROM 3 TO 6 PATIENTS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T21:13:00.000+02:00", "crawled": "2018-01-09T16:52:20.014+02:00", "highlightTitle": ""}